跳至主要内容
临床试验/EUCTR2021-000930-32-BE
EUCTR2021-000930-32-BE进行中(未招募)1 期

COVID-19: Documentation of humoral and cellular immune response of hemodialysis patients after vaccination against SARS-CoV-2 - COVID-19: immune response after COVID-vaccination in hemodialysis patients

AZ Sint-Jan Brugge-Oostende AV0 个研究点目标入组 580 人开始时间: 2021年3月4日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
580

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Consecutive series of hemodialysis patients receiving Covid-19 RNA
  • vaccine. A target of at least 100 patients is envisioned. Minimum age for
  • inclusion is 18 years.
  • 2. at least thirty healthy volunteers receiving Covid-19 RNA vaccine.
  • Minimum age for inclusion is 18 years. Individuals with immune
  • disorders cannot participate.
  • 3. at least thirty patients older than 50 years with at least 1
  • comorbidity (such as heart failure, diabetes, COPD, liver cirrhosis,....),
  • but no chronic renal insufficiency. Minimum age for inclusion is 18 years.
  • Only patients who receive vaccine on a voluntary basis will be included.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 550
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • - patients younger than 18 years old
  • - patients who do not voluntarily ask for a COVID-vaccination
  • - patients not eligible according to abovementioned inclusion criteria

研究者

相似试验